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Background: This retrospective study aims to assess the usefulness of SUVmax from FDG-PET imaging as a
prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT.
Methods: This study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage
IA/IB NSCLC. All patients were treated with 60Gy in 3 fractions with a median treatment time of six days. Local,
regional, and distant failures were evaluated independently according to the terms of RTOG1021. Local, regional,
and distant control, overall- and progression-free survival were estimated by the Kaplan-Meier method. Cox
proportional hazards regression was performed to determine whether SUVmax, age, KPS, gender, tumor size/T stage,
or smoking history influenced outcomes. SUVmax was evaluated as both a continuous and as a dichotomous
variable using a cutoff of <5 and ≥5.
Results: Median follow-up for the cohort was 16 months. Median OS and PFS were 25.3 and 40.3 months,
respectively. SUV with a cutoff value of 5 predicted for OS and PFS (p = .024 for each) but did not achieve
significance for LC (p = .256). On Cox univariate regression analysis, SUV as a dichotomous variable predicted for both
OS and PFS (p = .027 and p = .030, respectively). Defined as a continuous variable, SUVmax continued to predict for OS
and PFS (p = .032 and p = .003), but also predicted LC (p = .045) and trended toward significance for DC (p = .059).
SUVmax did not predict for OS as a dichotomous or continuous variable. It did, however, predict for PFS as a
continuous variable (p = .008), neared significance for local control (p = .057) and trended towards, significance for
distant control (p = .092).
Conclusions: SUVmax appears to be a statistically and clinically significant independent prognostic marker for
progression-free survival in patients with stage I NSCLC treated with SBRT. Prospective studies to more accurately
define the role of tumor FDG uptake in the prognosis of NSCLC are warranted.Introduction
[18 F]-Fluorodeoxyglucose positron emission tomography
(FDG-PET) is an important tool in the initial staging
and subsequent assessment of patients diagnosed and
treated for non-small cell lung cancer (NSCLC) [1,2].
FDG-PET imaging relies on the functional properties
that define malignancies including increased glucose* Correspondence: herond2@upmc.edu
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stated.metabolism. This uptake is linked to tumor proliferation
and metastatic potential and recent investigations dem-
onstrate the usefulness of PET imaging as a prognostica-
tor for eventual outcomes.
The International Association for the Study of Lung
Cancer (IASLC) reviewed 21 studies that assessed the util-
ity of the maximum standardized uptake value (SUVmax) in
NSCLC and determined that tumors with higher SUVmax
have poorer prognoses [3]. Other recent studies have
attempted to determine the utility of SUVmax under a more
narrow scope including that of early-stage NSCLC treatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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ging technique typically reserved for patients who are
medically-inoperable or who refuse surgery [4,5]. Multiple
studies demonstrate that pretreatment SUVmax predicts for
clinical outcomes in patients with early-stage NSCLC
treated with SBRT [6-8]. To the contrary, studies from
Cleveland Clinic and Indiana University failed to find a
correlation between pre-treatment SUVmax and survival
[9,10]. As early-stage NSCLC is a potentially curable dis-
ease with SBRT, here, an SUVmax cutoff that predicts for
more aggressive disease in patients with solitary, periph-
eral, primary stage I NSCLC is identified.
Methods and materials
Patients and workup
This study includes 95 non-consecutive patients treated
for biopsy-confirmed peripheral stage IA/IB between
October 2005 and May 2011 [11]. This research was de-
termined to have exemption status by our Institutional
Review Board. All patients were staged according to the
7th edition of the AJCC criteria. No tumor was located
within 2 cm of the proximal bronchial tree and no pa-
tient was previously treated for lung cancer. All patients
had a pre-SBRT FDG-PET-CT scan with a documented
SUVmax. Of these patients, 14 were operable candidates
but refused surgical therapy, while the remaining 81 pa-
tients had significant pulmonary or cardiac comorbidity
that precluded definitive surgical management (Table 1).
As a part of the staging, all patients underwent a PET-
CT scan. The SUVmax was obtained from review of the
formally dictated radiology report.
Simulation and treatment
Each patient was positioned supine with arms raised
above the head for the CT simulation. A thin-slice 4-D
high resolution CT (2.5 mm) and 1.25 mm helical CT
with intravenous contrast was obtained while the patient
was immobilized in a custom BodyFIX vacuum bag
(Electa). For patients treated with CyberKnife™, SynchronyTable 1 Patient characteristics
n = 95 Median
Age 77 (48-91) years
Sex
Male 49 (51.6%)
Female 46 (48.4%)
Operable 14 (14.7%)
Inoperable 81 (85.3%)
KPS
80-100 63 (66.3%)
<70 32 (32.7%)
Clinical follow-up 16.33 (1.13-64.2) monthsRespiratory Tracking System (Accuray, Inc, Sunnyvale,
CA) was utilized in conjunction with the 4D-CT to ensure
fiducial movement in sync with the GTV. For Trilogy™
and Trubeam™ patients, image-guided respiratory cycle
motion was accounted for via Varian Real-Time Position
Management System (Varian Medical Systems, Palo Alto,
CA). Respiratory gating was incorporated for patients with
tumor motion > 0.5 cm. The acquired images were then
transferred to the treatment planning workstation using
either Accuray MulitPLAN™ (Accuray, Inc, Sunnyvale,
CA) or Varian Eclipse™ (Varian Medical Systems, Palo
Alto, CA). The AAA planning algorithm was utilized for
patients treated on Trilogy™ and Trubeam™ and the pen-
cil beam algorithm for patients treated on CyberKnife™.
The tumor volume and any surrounding critical struc-
tures, including the spinal cord, heart, esophagus, bra-
chial plexus and normal lung, were manually delineated
by a radiosurgical team consisting of a radiation oncolo-
gist, a medical physicist, and a thoracic surgeon. The
gross tumor volume (GTV) was defined as the tumor
alone. To account for setup error and residual motion
detected on end-exhalation 4D-CT, a minimum expan-
sion of 5 mm margin was added to create the planning
target volume (PTV). An additional margin based on
motion assessment was added to create an internal tar-
get volume (ITV) to be used with gating. Dose-volume
histograms were calculated for the target volume and
nearby critical structures to select the optimal treatment
plan, which provided at least 95% of the prescription
dose to the PTV while sparing surrounding organs-at-
risk. If surrounding organs-at-risk were deemed to be at
excess risk for toxicity, a plan with lower PTV coverage
was accepted.
SBRT was performed using CyberKnife™ Robotic Ra-
diosurgery System (Accuray, Inc, Sunnyvale, CA for 39
patients, Trilogy™ Radiosurgery System (Varian Medical
Systems, Palo Alto, CA) for 54 patients and Trubeam™
Radiosurgery System (Varian Medical Systems, Palo
Alto, CA) for 2 patients. All lesions were treated with
heterogeneity correction to 60 Gy in 3 fractions every
other day with a median of 6 elapsed days from begin-
ning of treatment to end (range 3-21 days). For patients
treated on the Trilogy™ and Trubeam ™ platforms, cone-
beam CT (CBCT) was performed daily to separate setup
error from tumor reposition error. The treating phys-
ician checked and modified the alignment based on tar-
get relocalization in the fused imaging.
Disease assessment and clinical follow-Up
After treatment, patients were scheduled to have either a
CT or PET/CT scan every 3 months with a clinical evalu-
ation. Response to treatment was evaluated by the RECIST
v1.1 criteria and documented as a complete response, par-
tial response (greater than 30% decrease in the longest
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longest axis), or stable disease (neither partial response
nor progressive disease) [12]. Follow-up imaging was re-
evaluated to classify local, regional, and distant failures
similar to the definitions of RTOG 1021 [13]. Local fail-
ures were defined as recurrence within the originally in-
volved lobe or within 2 cm of the initial primary but
located outside the originally involved lobe. Regional fail-
ure included non-involved ipsilateral lobes, as well as ipsi-
lateral hilar, mediastinal, and subcarinal lymph nodes.
Distant failures enveloped ipsilateral supraclavicular and
contralateral lymph nodes and all other distant sites.
Progression-free survival was defined as the time to a spe-
cified recurrence and was measured from the last day of
treatment to that event. Death was not included as an
endpoint for PFS. Local, regional, and distant control,
overall- and progression-free survival were estimated by
the Kaplan-Meier method. The ANOVA test was utilized
to determine correlations between SUVmax, tumor hist-
ology, and stage. Forward conditional Cox proportional
hazards regression was performed to determine whether
SUVmax (continuous/dichotomous), age (continuous), KPS
(continuous), gender, tumor T stage, tumor histology, or
smoking pack years (continuous) influenced outcomes.
SUVmax was evaluated in univariate and multivariate ana-
lyses as both a continuous and as a dichotomous variable
using a cutoff of <5 and ≥5 as described in previous re-
ports [6,9,14,15]. All statistics were completed using SPSS
version 20 (IBM Corp, Armonk, NY). Significance was set
at p ≤ 0.05.
Results
A total of 95 patients with a median age 77 years (range:
48-91 years) were identified between October 2005 and
May 2011 (Table 1). All patients had biopsy-confirmed
NSCLC, with 38 (40%) having squamous cell carcinoma
and 33 (34.7%) having adenocarcinoma. The remainingTable 2 Imaging and tumor characteristics with percentage d
N (%)
All patients 95
Histology
Squamous 38 (40%)
Adenocarcinoma 33 (34.7%)
NSCLC NOS 24 (25.3%)
Tumor Size [median (range)] 2.15 (0.8-5.0) cm
T Stage
1a 46 (48.4%)
1b 30 (31.6%)
2a 19 (20%)
Tumor demographics and SUVmax distributions showing tendency for squamous ce24 (25.3%) were not differentiated beyond NSCLC NOS.
The median tumor size was 2.15 cm (range: 0.8-5.0 cm).
Tumor T-stage distribution was, according to the AJCC
7th edition, as follows: T1a: 46 (48.4%), T1b: 30 (31.6%),
and T2a: 19 (20%) (Table 2). The median pretreatment
SUVmax was 6.6 (range: 1.2-26.1). Among the 95 pa-
tients, 90 had follow-up imaging available (median num-
ber of scans: 2) for review with a median follow-up time
of 16 months (range: 1-63 months). Imaging was per-
formed to assess changes in tumor size, to identify de-
velopment of additional tumors, and to evaluate effects
on normal tissues. Of the patients who had follow-up
imaging, 82 had at least one PET-CT scan.
PET response
Of the 82 who had at least one PET scan in follow-up, at
first PET-CT scan, 6 achieved complete responses, 56 a
partial response, 24 stable disease, and 2 progressive dis-
ease. During interval follow-up, the best response observed
was: 21 complete responders, 49 partial responders, 19
with stable disease, and none with progressive disease.
Toxicity
In the 95 patients treated with SBRT, three acute Grade
3 toxicities were observed. The Grade 3 toxicities were
comprised of radiation pneumonitis, pneumonia, and
pleural effusion. Additionally, there was one Grade 2
dyspnea and two Grade 2 chest pains. Late toxicities in-
cluded one Grade 3 dyspnea and one Grade 2 dyspnea.
Clinical outcomes
Median overall survival (OS) and progression-free sur-
vival (PFS) were 25.3 and 40.3 months, respectively. The
2-year actuarial rates of events following treatment are
shown in Table 3. Two-year overall and cause-specific
survivals were 64.2% and 94.5%, respectively. Overall
PFS at two years was 93.7%. Two-year local control wasistribution per SUVmax category
Pretreatment PET SUVmax
SUVmax < 5 SUVmax ≥ 5 p
40 55 ns
8 (20%) 30 (54.5%) .046
21 (52.5%) 12 (21.8%)
11 (27.5%) 13 (23.7%)
1.95 (0.9-5.0) cm 2.4 (0.8-4.8) cm .022
27 (67.5%) 19 (34.5%) .013
7 (17.5%) 23 (41.8%)
6 (15%) 13 (23.7%)
ll histology and larger size to be of increasing SUVmax.
Table 3 Overall outcomes from treatment with 2-year event rates showing differences between SUVmax categories
SUVmax < 5 SUVmax ≥ 5
2-year freedom from event (%) Total events n (%) 2-year freedom (%) 2-year freedom (%) K-M p
Local failure 93.7 8 (8.4) 97 86 .256
Regional failure 90.5 10 (10.5) 94 82 .131
Distant failure 86.3 15 (15.8) 91 78 .371
Any progression 93.7 25 (26.3) 88 62 .024
Death 64.2 48 (50.5) 72 49 .024
Comparison of SUVmax categories shows a statistically significant difference in progression-free and overall survivals.
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was 86.3%. For dichotomous variable analyses, an SUV
of 5 was utilized as a cutoff as stated above. In univariate
Kaplan-Meier analysis, OS was predicted by TNM T-
stage (p = .007). There was no difference in survival be-
tween operable and non-operable patients (p = .313) or
tumor histology (p = .292). SUVmax predicted for OS and
PFS (p = .024 for each, Figures 1A, B) but did not
achieve significance for local control (LC) (p = 0.256), re-
gional control (RC) (p = 0.131), or distant control (DC)
(p = 0.371) (Figures 2A, B, C). On Cox univariate regres-
sion analysis, SUVmax as a dichotomous variable predicted
for both OS (p = .027, HR = 0.478) and PFS (p = .030,
HR = 0.359). OS was also predicted by Karnofsky Per-
formance Status (p < .0001) and TNM T-stage (p = .005).
Defined as a continuous variable, SUVmax continued to
predict for OS (p = .032, HR = 1.061) and PFS (p = .003,
HR = 1.098), but also achieved significance for LC
(p = .045, HR = 1.124) and trended toward significance
for DC (p = .059) (Table 4). On ANOVA test, tumor T-
stage and histology were both significantly correlated to
SUVmax (p = .046 and p = .013, respectively).Figure 1 Overall and progression-free survivals as differentiated by S
p= 0.024; B: Progression-free survival differences between SUVmax categorieIn multivariate analysis, SUVmax did not predict for OS
as a dichotomous or continuous variable and only KPS and
T-stage remained significant (p < .0001 and p = .013, re-
spectively). It did, however, predict for PFS as a continuous
variable (p = .008, HR = 1.111), though not as a dichotom-
ous variable (Table 4). SUVmax also trended toward signifi-
cance for LC and DC as a continuous variable (p = .057
and p = .092, respectively).
Discussion
Previous reports indicate that tumor aggressiveness de-
fined by an increased Ki-67 is correlated with SUVmax and
tumor differentiation but not with TNM stage [16,17].
Lung tumors with high Ki-67 are associated with de-
creased survival [18] as well as shortened progression-free
survival in surgical series [19,20]. This would indicate
that tumors with higher SUVmax values have an in-
creased likelihood of having a more aggressive biology
regardless of size which in our study, manifests in de-
creased progression-free survival.
Our study of patients with primary, peripheral, biopsy-
proven, stage I NSCLC treated with a homogenous SBRTUVmax. A: Overall survival differences between SUVmax categories,
s, p= 0.024.
Figure 2 Local, regional, and distant control rates as differentiated by SUVmax. A: Local control differences between SUVmax categories,
p= 0.256; B: Regional control differences between SUVmax categories, p= 0.131; C: Distant control differences between SUVmax categories, p= 0.371.
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survival. OS was predicted by tumor stage, a finding that
is expected. When analyzing SUV cutoffs for significance,
a range of SUV values showed significant results for differ-
ent endpoints. A meta-analysis of surgical studies utilizing
differing SUV cutoffs by Paesmans et al also found that
SUVmax is a significant prognosticator for overall sur-
vival [3].
To date, similar studies on patients treated with either
conventionally fractionated radiation therapy or SBRT
have been unable to come to consensus on the utility of
SUVmax as a prognosticator [6-10,15,21]. Ikushima et al’s
study of definitive external beam radiation found SUVmaxTable 4 Univariate and multivariate Cox proportional
hazards regression analysis with SUVmax as a
dichotomous and continuous variable
Univariate Cox proportional hazards regression analysis
PET SUVmax
(<5 vs ≥5)
PET SUVmax
(Continuous)
HR (95% CI) p HR (95% CI) p
Local control – NS 1.124 (1.002 – 1.260) .045
Distant control – NS – .059
Progression-
free survival
0.359 (0.143 – 0.905) .030 1.098 (1.033 – 1.168) .003
Overall survival 0.478 (0.249 – 0.920) .027 1.061 (1.005 – 1.119) .032
Multivariate Cox proportional hazards regression analysis
Local control – NS – .057
Distant control – NS – .092
Progression-
free survival
– .105 1.111 (1.027 – 1.201) .008
Univariate Cox hazards regression analysis of SUVmax as a dichotomous
variable shows significance for progression-free and overall survivals. As a
continuous variable, SUVmax significantly predicts for local control, progression-
free and overall survivals. In multivariate Cox analysis, SUVmax remains a
significant predictor of progression-free survival.to be related to tumor size/stage but not outcomes and
hypothesized that the result was due to partial volume
effect (PVE) as outlined by Soret et al [21,22]. In this
study, we also found SUVmax to be related to tumor size
(p = .013), but tumor size did not predict for the same out-
comes as SUVmax. The results from Ikushima et al’s study
are in contrast to the results from the Sasaki group, which
showed an SUV cutoff of 5 to be significant for OS and
PFS in patients treated with conventional RT [15]. In the
two studies which investigated SUVmax as a prognostic
factor for the treatment of early-stage NSCLC with SBRT
and failed to achieve significance, both cite sample size as
a possible contributor to the lack of findings [9,10]. The
studies that did find significance in SUVmax as a predictor
of outcomes also suffer from problems such as heteroge-
neous treatment dosing, tumor staging and location, and
sample size [6-8]. With a reduction in confounding vari-
ables by evaluating patients with a uniformity in stage,
treatment dose and fractionation, and confirmation that
all patients do indeed have non-small cell lung cancer,
this study is able to provide a more focused insight into
the prognostic value of SUVmax. An additional study by
Abelson et al. infers that the amount of metabolically
active tumor may be equally important to outcomes as
the peak metabolic activity of the tumor and warrants
further investigation to elucidate the relationship be-
tween the two [23].
To better determine the external validity of the results
of this study, the most appropriate SUVmax cutoff needs
to be generated from pooled data from multiple high-
volume centers. To determine the applicability of this in-
formation to the general stage 1 SBRT lung population,
this data needs to include patients without pathological
confirmation of disease as well as those who were treated
under alternative fractionation schedules. Additionally,
studies that include medically operable patients will
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on inoperable patients, most of whom succumb to inter-
current disease. At the time of analysis in this study, the
cause of death in at least 56% of the patients who had per-
ished was attributable to intercurrent disease. Armed with
the upfront knowledge that some patients have more ag-
gressive disease than others, as well as the emerging evi-
dence that early post-treatment FDG-PET scanning may
allow further differentiation of at-risk patients [6], clinical
trials may emerge to offer treatment-intensification.
There are several limitations to this study including size,
limited follow-up, its retrospective nature, and the inherent
variability of FDG-PET scans and SUVmax measurements
from machine to machine and interobserver variability. A
multi-institutional prospective study which utilizes a stan-
dardized protocol for administering and reading FDG-PET
scans as well as biopsy information to correlate tumor biol-
ogy to scan information and outcomes is likely necessary
to confirm the findings found herein.
SUVmax appears to be a useful prognosticator for
progression-free survival and overall survival in the
therapy of early-stage NSCLC treated with SBRT. As a
predictor in both dichotomous and continuous forms,
SUVmax seems to be correlated with the propensity of
tumors to metastasize. Larger studies may reveal a more
appropriate cutoff value for identifying patients with
more aggressive disease, which may then provide the
basis for clinical trials to identify the benefit of more
vigorous therapy.
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